The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.

RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

Elias Jabbour, MD, discusses the role of bosutinib as a standard treatment for patients with CML that is resistant or intolerant to prior TKI therapy.

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Bora Lim, MD, discusses the significance of the FDA approval of adjuvant ribociclib for patients with HR-positive, HER2-negative breast cancer.

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

Tapotoclax showed manageable safety, and it reduced bone marrow blasts and transfusion dependence in MDS after HMAs.

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Guillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Naval G. Daver, MD, discusses the potential utility of uproleselan in relapsed/refractory acute myeloid leukemia.

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.